Publications by authors named "Hiroko Ikenaga"

Article Synopsis
  • Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are serious global health issues, making effective treatment a challenge.
  • Peroxisome proliferator-activated receptors (PPARs) are key proteins that help regulate lipid metabolism and have three main types: PPARα, PPARβ/δ, and PPARγ.
  • New therapies are being explored using nanoparticles (NPs) that specifically target PPARα and PPARγ, enhancing drug delivery systems for treating MASLD/MASH.
View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is associated with increased soluble CD40 levels. This study aimed to investigate CD40's role in liver tumor progression. CD40 levels were examined in HCC patient tissues and various HCC cell lines, and their interaction with CD4T cells was studied.

View Article and Find Full Text PDF

Intracellular gap (iGap) formation in liver sinusoidal endothelial cells (LSECs) is caused by the destruction of fenestrae and appears under pathological conditions; nevertheless, their role in metastasis of cancer cells to the liver remained unexplored. We elucidated that hepatotoxin-damaged and fibrotic livers gave rise to LSECs-iGap formation, which was positively correlated with increased numbers of metastatic liver foci after intrasplenic injection of Hepa1-6 cells. Hepa1-6 cells induced interleukin-23-dependent tumor necrosis factor-α (TNF-α) secretion by LSECs and triggered LSECs-iGap formation, toward which their processes protruded to transmigrate into the liver parenchyma.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) has high recurrence rates. HCC sometimes progresses from early-stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage 0/A) to advanced-stage HCC after repeated recurrences and treatments. HCC progression deteriorates quality of life and prognosis.

View Article and Find Full Text PDF

Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-related hemorrhage as a lenvatinib-related adverse event have not been elucidated.

View Article and Find Full Text PDF